Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer

…, R Kumanishi, K Kato, K Sugiyama, S Mitani… - Journal of global …, 2019 - ascopubs.org
PURPOSE We previously reported on the pilot study assessing the feasibility of using the
Japanese translation of the Comprehensive Score for Financial Toxicity (COST) tool to …

[HTML][HTML] Emerging targeted therapies for HER2 positive gastric cancer that can overcome trastuzumab resistance

S Mitani, H Kawakami - Cancers, 2020 - mdpi.com
Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 (HER2),
has improved survival in patients with HER2-positive advanced gastric or gastroesophageal …

Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer

K Sugiyama, Y Narita, S Mitani, K Honda… - Anticancer …, 2018 - ar.iiarjournals.org
Aim: To determine the association between sarcopenia and prognosis in patients with
metastatic gastric cancer (mGC) receiving chemotherapy. Patients and Methods: Our study …

[HTML][HTML] Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature

S Mitani, S Kadowaki, A Komori, K Sugiyama, Y Narita… - Medicine, 2017 - journals.lww.com
Acute hyperammonemic encephalopathy induced by fluoropyrimidines (FPs) is a rare
complication. Its pathophysiology remains unclear, especially given the currently used regimens, …

[HTML][HTML] A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

…, B Gyawali, M Ando, K Sugiyama, S Mitani… - …, 2018 - ncbi.nlm.nih.gov
Background Financial toxicity (FT) has a negative impact on the quality of life and survival of
patients with cancer. The comprehensive score for FT (COST) questionnaire is a tool to …

FOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasis

…, M Kondo, A Komori, K Sugiyama, S Mitani… - Anticancer …, 2017 - ar.iiarjournals.org
Background/Aim: Severe peritoneal metastasis (PM) from advanced gastric cancer (AGC)
causes massive ascites and inadequate oral intake. Because patients with severe PM are …

[HTML][HTML] Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck …

T Kurosaki, S Mitani, K Tanaka, S Suzuki… - Anti-Cancer …, 2021 - journals.lww.com
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic …

[HTML][HTML] Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small …

…, Y Chiba, J Tanizaki, R Kato, S Mitani… - European Journal of …, 2022 - Elsevier
Background Tumour burden (TB) is implicated in resistance to programmed cell death-1/PD-L1
inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to …

Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis

S Mitani, S Kadowaki, I Oze, T Masuishi… - Cancer …, 2020 - Wiley Online Library
Background Esophageal cancer is associated with synchronous or metachronous cancer at
other primary sites. However, few studies have evaluated the second malignancies after the …

Efficacy of cytotoxic agents after progression on anti-PD-(L) 1 antibody for pre-treated metastatic gastric cancer

K Kato, Y Narita, S Mitani, K Honda… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: The efficacy of treatment using the anti-programmed cell death-1 (anti-PD-1)
antibody for metastatic gastric cancer (mGC) has been established previously. …